Literature DB >> 11448155

Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation and generates resistance to apoptosis on matrix withdrawal through PKB/Akt.

A Rangarajan1, R Syal, S Selvarajah, O Chakrabarti, A Sarin, S Krishna.   

Abstract

Invasive cervical tumors, a major subset of human epithelial neoplasms, are characterized by the consistent presence of papillomavirus oncogenes 16 or 18 E6 and E7 products. Cervical tumors also consistently exhibit cytosolic and nuclear forms of Notch1, suggesting the possible persistent activation of the Notch pathway. Here we show that activated Notch1 synergizes with papillomavirus oncogenes in transformation of immortalized epithelial cells and leads to the generation of resistance to anoikis, an apoptotic response induced on matrix withdrawal. This resistance to anoikis by activated Notch1 is mediated through the activation of PKB/Akt, a key effector of activated Ras in transformation. We suggest that activated Notch signaling may serve to substitute for the lack of activated Ras mutations in the majority of human cervical neoplasms. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448155     DOI: 10.1006/viro.2001.0867

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  49 in total

Review 1.  Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression.

Authors:  Oishee Chakrabarti; Sudhir Krishna
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

2.  Notch-activated signaling cascade interacts with mitochondrial remodeling proteins to regulate cell survival.

Authors:  Lakshmi R Perumalsamy; Manjula Nagala; Apurva Sarin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-25       Impact factor: 11.205

3.  Human papillomavirus 16E6 and NFX1-123 potentiate Notch signaling and differentiation without activating cellular arrest.

Authors:  Portia A Vliet-Gregg; Jennifer R Hamilton; Rachel A Katzenellenbogen
Journal:  Virology       Date:  2015-02-25       Impact factor: 3.616

Review 4.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

Review 5.  miRNAs stem cell reprogramming for neuronal induction and differentiation.

Authors:  Claire Perruisseau-Carrier; Marcin Jurga; Nico Forraz; Colin P McGuckin
Journal:  Mol Neurobiol       Date:  2011-03-29       Impact factor: 5.590

6.  CD66+ cells in cervical precancers are partially differentiated progenitors with neoplastic traits.

Authors:  Chitra Pattabiraman; Shiyuan Hong; Vignesh K Gunasekharan; Annapurna Pranatharthi; Jeevisha Bajaj; Sweta Srivastava; H Krishnamurthy; Aswathy Ammothumkandy; Venkat G Giri; Laimonis A Laimins; Sudhir Krishna
Journal:  Cancer Res       Date:  2014-09-29       Impact factor: 12.701

7.  Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.

Authors:  Hong Qiu; Patrick M Zmina; Alex Y Huang; David Askew; Barbara Bedogni
Journal:  Cancer Lett       Date:  2018-07-21       Impact factor: 8.679

8.  Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation.

Authors:  Claudio Talora; Dennis C Sgroi; Christopher P Crum; G Paolo Dotto
Journal:  Genes Dev       Date:  2002-09-01       Impact factor: 11.361

9.  Human papilloma virus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis.

Authors:  Massimiliano Mellone; Christian Rinaldi; Isabella Massimi; Marialaura Petroni; Veronica Veschi; Claudio Talora; Silvia Truffa; Helena Stabile; Luigi Frati; Isabella Screpanti; Alberto Gulino; Giuseppe Giannini
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

10.  Notch1 regulates the functional contribution of RhoC to cervical carcinoma progression.

Authors:  S Srivastava; B Ramdass; S Nagarajan; M Rehman; G Mukherjee; S Krishna
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.